Recent insights into the pathogenesis of hepatic encephalopathy and treatments

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Expert Review of Gastroenterology & Hepatology

• Publication date

  2014-01-01

• Fields of study

  Medicine, Environmental Science

• Identifiers
  DOI 10.1586/17474124.2014.858598PMID 24236755
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cerebral oedema is rare in acute‐on‐chronic liver failure patients presenting with high‐grade hepatic encephalopathy

  2014cited by this paper
• Ammonia clearance with haemofiltration in adults with liver disease

  2014cited by this paper
• Cerebral oedema is not responsible for motor or cognitive deficits in rats with hepatic encephalopathy

  2014cited by this paper
• Current topics in therapeutic plasmapheresis

  2014cited by this paper
• Inflammation and hepatic encephalopathy.

  2013cited by this paper
• Lessons from look-back in acute liver failure? A single centre experience of 3300 patients.

  2013cited by this paper
• Glycerol Phenylbutyrate in Patients With Cirrhosis and Episodic Hepatic Encephalopathy: A Pilot Study of Safety and Effect on Venous Ammonia Concentration

  2013cited by this paper
• The nutritional management of hepatic encephalopathy in patients with cirrhosis: International society for hepatic encephalopathy and nitrogen metabolism consensus

  2013cited by this paper
• A Randomized, Double-Blind, Controlled Trial Comparing Rifaximin Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy

  2013cited by this paper
• Circulating neutrophil dysfunction in acute liver failure

  2013cited by this paper
• Systemic inflammation and ammonia in hepatic encephalopathy

  2013cited by this paper
• Role of branched chain amino acids in cerebral ammonia homeostasis related to hepatic encephalopathy

  2013cited by this paper
• Sildenafil citrate attenuates the deleterious effects of elevated ammonia

  2013cited by this paper
• Efficacy of liver assisting in patients with hepatic encephalopathy with special focus on plasma exchange

  2013cited by this paper
• Oral branched-chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials.

  2013cited by this paper
• Safety of Ornithine Phenylacetate in Cirrhotic Decompensated Patients: An Open-label, Dose-escalating, Single-cohort Study

  2013cited by this paper
• The liver–brain axis in liver failure: neuroinflammation and encephalopathy

  2013cited by this paper
• Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?

  2013cited by this paper
• Real-time analysis of microglial activation and motility in hepatic and hyperammonemic encephalopathy.

  2012cited by this paper
• Rifaximin reduces endotoxemia and improves liver function and disease severity in patients with decompensated cirrhosis

  2012cited by this paper
• Carnitine deficiency presenting with encephalopathy and hyperammonemia in a patient receiving chronic enteral tube feeding: a case report

  2012cited by this paper
• Introduction to the Revised American Association for the Study of Liver Diseases Position Paper on Acute Liver Failure 2011

  2012cited by this paper
• The neurological manifestations of acute liver failure.

  2012cited by this paper
• Ammonia‐Lowering Strategies for the Treatment of Hepatic Encephalopathy

  2012cited by this paper
• Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy

  2012cited by this paper
• PMO-123 Gene transfer of dimethylarginine dimethylaminohydrolase-1 reduces portal pressure in a rodent model of cirrhosis

  2012cited by this paper
• Probiotics for patients with hepatic encephalopathy.

  2011cited by this paper
• Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study.

  2011cited by this paper
• Biologic properties and clinical uses of rifaximin

  2011cited by this paper
• Adult liver transplantation in the USA

  2011cited by this paper
• Minimal hepatic encephalopathy.

  2011cited by this paper
• Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy

  2011cited by this paper
• 56 THE PROPHYLACTIVE EFFECT OF MILD HYPOTHERMIA TO PREVENT BRAIN EDEMA IN PATIENTS WITH ACUTE LIVER FAILURE: RESULTS OF A MULTICENTER RANDOMIZED, CONTROLLED TRIAL

  2011cited by this paper
• AST‐120 (spherical carbon adsorbent) lowers ammonia levels and attenuates brain edema in bile duct–ligated rats

  2011cited by this paper
• Rifaximin in the treatment of hepatic encephalopathy

  2011cited by this paper
• Interorgan ammonia metabolism in liver failure: the basis of current and future therapies

  2011cited by this paper
• Urinary ammonia excretion increases acutely during living donor liver transplantation

  2011cited by this paper
• Acute Hepatic (or Hyperammonemic) Encephalopathy: Diffuse Cortical Injury and the Significance of Ammonia

  2011cited by this paper
• Acetyl-l-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy

  2011cited by this paper
• Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis.

  2011cited by this paper
• A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy

  2011cited by this paper
• Acetyl-L-carnitine improves cognitive functions in severe hepatic encephalopathy: a randomized and controlled clinical trial

  2011cited by this paper
• Immune dysfunction and infections in patients with cirrhosis.

  2011cited by this paper
• Gut flora and hepatic encephalopathy in patients with cirrhosis.

  2010cited by this paper
• Hyperammonemia induces neuroinflammation that contributes to cognitive impairment in rats with hepatic encephalopathy.

  2010cited by this paper
• Rifaximin treatment in hepatic encephalopathy.

  2010cited by this paper
• Diagnosis and Prognostic Significance of Minimal Hepatic Encephalopathy in Patients with Cirrhosis of Liver

  2010cited by this paper
• Neurones express glutamine synthetase when deprived of glutamine or interaction with astrocytes

  2010cited by this paper
• Ammonia and the neutrophil in the pathogenesis of hepatic encephalopathy in cirrhosis

  2010cited by this paper
• N-Acetylcysteine attenuates cerebral complications of non-acetaminophen-induced acute liver failure in mice: antioxidant and anti-inflammatory mechanisms

  2010cited by this paper
• Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis

  2010cited by this paper
• Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis: An Open-Label, Randomized Controlled Trial of Lactulose, Probiotics, and No Therapy

  2010cited by this paper
• Minocycline attenuates oxidative/nitrosative stress and cerebral complications of acute liver failure in rats.

  2009cited by this paper
• Branched chain amino acids supplemented with L-acetylcarnitine versus BCAA treatment in hepatic coma: a randomized and controlled double blind study

  2009cited by this paper
• 105 PHASE 2, MULTICENTER, RANDOMIZED STUDY OF AST-120 (SPHERICAL CARBON ADSORBENT) VS. LACTULOSE IN THE TREATMENT OF LOW-GRADE HEPATIC ENCEPHALOPATHY (HE)

  2009cited by this paper
• Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure.

  2009cited by this paper
• Identifying the direct effects of ammonia on the brain

  2009cited by this paper
• Hyperammonemia increases GABAergic tone in the cerebellum but decreases it in the rat cortex.

  2009cited by this paper
• Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study.

  2009cited by this paper
• Glutamatergic and gabaergic neurotransmission and neuronal circuits in hepatic encephalopathy

  2009cited by this paper
• Paper alert

  2009cited by this paper
• Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo.

  2009cited by this paper
• Minimal hepatic encephalopathy is associated with motor vehicle crashes: The reality beyond the driving test

  2009cited by this paper
• Minimal hepatic encephalopathy

  2009cited by this paper
• Direct Evidence for Central Proinflammatory Mechanisms in Rats with Experimental Acute Liver Failure: Protective Effect of Hypothermia

  2009cited by this paper
• IL-6 and IL-18 in Blood May Discriminate Cirrhotic Patients With and Without Minimal Hepatic Encephalopathy

  2009cited by this paper
• The brain in acute liver failure. A tortuous path from hyperammonemia to cerebral edema

  2009cited by this paper
• Gut ammonia production and its modulation

  2009cited by this paper
• Hepatic encephalopathy and fitness to drive.

  2009cited by this paper
• L‐ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure

  2009cited by this paper
• Cerebral inflammation contributes to encephalopathy and brain edema in acute liver failure: protective effect of minocycline

  2009cited by this paper
• A critical analysis of studies assessing L-ornithine-L-aspartate (LOLA) in hepatic encephalopathy treatment.

  2009cited by this paper
• Interorgan ammonia trafficking in liver disease

  2009cited by this paper
• Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy

  2009cited by this paper
• Therapeutic hypothermia for acute liver failure

  2009cited by this paper
• Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis

  2008cited by this paper
• An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy

  2008cited by this paper
• Hyperammonemic Encephalopathy Caused by Carnitine Deficiency

  2008cited by this paper
• Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis.

  2008cited by this paper
• Acetyl-l-Carnitine Treatment in Minimal Hepatic Encephalopathy

  2008cited by this paper
• Ammonia impairs neutrophil phagocytic function in liver disease

  2008cited by this paper
• Survival after treatment with phenylacetate and benzoate for urea-cycle disorders.

  2007cited by this paper
• Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome

  2007cited by this paper
• Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis

  2007cited by this paper
• L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy.

  2007cited by this paper
• Role of ammonia and inflammation in minimal hepatic encephalopathy

  2007cited by this paper
• Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure

  2007cited by this paper
• Lactulose improves cognitive functions and health‐related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy

  2007cited by this paper
• Endotoxemia produces coma and brain swelling in bile duct ligated rats

  2007cited by this paper
• NMDA receptors in hyperammonemia and hepatic encephalopathy

  2007cited by this paper
• Bifidobacterium longum with Fructo-Oligosaccharide (FOS) Treatment in Minimal Hepatic Encephalopathy: A Randomized, Double-Blind, Placebo-Controlled Study

  2007cited by this paper
• Inflammation and hepatic encephalopathy: Ibuprofen restores learning ability in rats with portacaval shunts

  2007cited by this paper
• Role of extracellular cGMP and of hyperammonemia in the impairment of learning in rats with chronic hepatic failure. Therapeutic implications.

  2006cited by this paper
• Effects of l-Acetylcarnitine on Cirrhotic Patients with Hepatic Coma: Randomized Double-Blind, Placebo-Controlled Trial

  2006cited by this paper
• Glutamine: A Trojan horse in ammonia neurotoxicity

  2006cited by this paper
• Hyperammonemia increases sensitivity to LPS.

  2006cited by this paper
• Brain metabolism of 13N‐ammonia during acute hepatic encephalopathy in cirrhosis measured by positron emission tomography

  2006cited by this paper
• Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study.

  2006cited by this paper
• Encephalopathy due to carnitine deficiency in an adult patient with gluten enteropathy.

  2006cited by this paper
• The challenge of understanding ammonium homeostasis and the role of the Rh glycoproteins.

  2006cited by this paper

• Neurological Symptoms in Cirrhotic Patients – Not Always Encephalopathy

  2025cites this paper
• Brain Changes in Alcohol Induced Liver Cirrhosis Patients: Insights from Quantitative Susceptibility Mapping

  2025cites this paper
• Progress in pathogenesis and treatment of type A hepatic encephalopathy in acute liver failure: a comprehensive review

  2024cites this paper
• The pathogenesis of gut microbiota in hepatic encephalopathy by the gut–liver–brain axis

  2023cites this paper
• Molecular mechanisms involved in the effects of morin in experimental hepatic encephalopathy

  2022cites this paper
• The contributions of bacteria metabolites to the development of hepatic encephalopathy

  2022cites this paper
• Neuropathological report of propionic acidemia

  2022influential citation
• Comparative Effectiveness and Safety of Polyethylene Glycol Electrolyte Solution Versus Lactulose for Treatment of Hepatic Encephalopathy

  2021cites this paper
• Low Serum 25-Hydroxy Vitamin D (25-OHD) and Hepatic Encephalopathy in HCV-Related Liver Cirrhosis

  2021cites this paper
• Challenges in clinical breath research development

  2020cites this paper
• Activation of Protein Kinase Cδ Contributes to the Induction of Src/EGF Receptor/ERK Signaling in Ammonia-treated Astrocytes

  2020influential citation
• Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.

  2019cites this paper
• Acetyl-L-carnitine for patients with hepatic encephalopathy.

  2019influential citation
• Microbiota facilitates the formation of the aminated metabolite of green tea polyphenol (‐)‐epigallocatechin‐3‐gallate which trap deleterious reactive endogenous metabolites

  2019cites this paper
• Hepatic Encephalopathy: Classification, Diagnosis, and Treatment

  2019cites this paper
• Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified

  2019cites this paper
• Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis

  2019cites this paper
• Diabetes as a Risk Factor Hepatic Encephalopathy among Egyptian Cirrhotic Patients

  2019cites this paper
• Pro-inflammatory cytokines serve as communicating molecules between the liver and brain for hepatic encephalopathy pathogenesis and Lycium barbarum polysaccharides protection.

  2019cites this paper
• Disorders of the Liver

  2018cites this paper
• Is treating the gut microbiome the key to achieving better outcomes in cirrhosis?

  2018cites this paper
• The assessment and care of patients with hepatic encephalopathy.

  2017cites this paper
• Commiphora molmol Modulates Glutamate-Nitric Oxide-cGMP and Nrf2/ARE/HO-1 Pathways and Attenuates Oxidative Stress and Hematological Alterations in Hyperammonemic Rats

  2017cites this paper
• Insights to Indications and Harm of Proton Pump Inhibitors Usage in Patients with Liver Cirrhosis

  2017cites this paper
• Diseases of the Liver and Liver Failure

  2017cites this paper
• Ammonia Transporters and Their Role in Acid-Base Balance.

  2017cites this paper
• Serum 25-hydroxyvitamin D deficiency and hepatic encephalopathy in chronic liver disease

  2017cites this paper
• Polyethylene Glycol and Lactulose versus Lactulose Alone in the Treatment of Hepatic Encephalopathy in Patients with Cirrhosis: A Non-Inferiority Randomized Controlled Trial

  2017cites this paper
• Screening ssDNA aptamers against HIV P24 antigen using agarose beads as carriers

  2017cites this paper
• Current state of knowledge of hepatic encephalopathy (part I): newer treatment strategies for hyperammonemia in liver failure

  2016cites this paper
• Development of an experimental rat model of hyperammonemic encephalopathy and evaluation of the effects of rifaximin.

  2016cites this paper
• A novel ammonia lowering strategy for the treatment of intracranial hypertension in acute liver failure

  2016cites this paper
• Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites

  2016cites this paper
• Neurologic Manifestations of Systemic Disease ( N Scolding and C Rice , Section Editors ) Management of Neurologic Manifestations in Patients with Liver Disease

  2016cites this paper
• Lactulose vs Polyethylene Glycol for Treatment of Hepatic Encephalopathy.

  2015cites this paper
• Risks and benefits of resumption of anticoagulation following traumatic brain injury remain complex and uncertain.

  2015cites this paper
• Lactulose vs Polyethylene Glycol for Treatment of Hepatic Encephalopathy.

  2015cites this paper
• To Break or to Brake Neuronal Network Accelerated by Ammonium Ions?

  2015cites this paper
• Hepatic encephalopathy: New treatments

  2015cites this paper
• Diabetes as a risk factor for hepatic encephalopathy in cirrhosis patients.

  2015cites this paper
• Risks and benefits of resumption of anticoagulation following traumatic brain injury remain complex and uncertain-reply.

  2015cites this paper
• Hepatic encephalopathy coexists with acquired chronic hepatocerebral degeneration

  2015cites this paper
• Breath ammonia and ethanol increase in response to a high protein challenge

  2015cites this paper
• Minimal hepatic encephalopathy characterized by parallel use of the continuous reaction time and portosystemic encephalopathy tests

  2015cites this paper
• Current concepts in minimal hepatic encephalopathy.

  2015cites this paper
• Viability assessment of magnetic resonance spectroscopy for the detection of minimal hepatic encephalopathy severity.

  2015cites this paper
• Therapeutic Effects and Mechanisms of Action of Rifaximin in Gastrointestinal Diseases.

  2015cites this paper
• Updates in the pathogenesis and diagnosis of hepatic encephalopathy.

  2014cites this paper
• Acetyl‐L‐carnitine for patients with hepatic encephalopathy

  2014cites this paper